McCluggage W G
Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland.
J Clin Pathol. 2002 May;55(5):321-5. doi: 10.1136/jcp.55.5.321.
Uterine carcinosarcomas (malignant mixed Mullerian tumours) are highly aggressive and have traditionally been regarded as a subtype of uterine sarcoma. However, in recent years convincing evidence has suggested that most, but not all, are monoclonal in origin rather than true collision tumours. Data confirm that the carcinomatous element is the "driving force" and that the sarcomatous component is derived from the carcinoma or from a stem cell that undergoes divergent differentiation. Thus, uterine carcinosarcomas are best regarded as metaplastic carcinomas, although the designation carcinosarcoma is likely to remain. Adjuvant treatment for uterine carcinosarcoma should probably be similar to that directed against aggressive high grade endometrial carcinomas rather than being sarcoma based. Importantly, a small proportion of uterine carcinosarcomas are true collision tumours and should be recognised as such because, in some instances, the prognosis may be better than for a similar stage carcinosarcoma.
子宫癌肉瘤(恶性苗勒管混合瘤)具有高度侵袭性,传统上被视为子宫肉瘤的一种亚型。然而,近年来有确凿证据表明,大多数(但并非全部)癌肉瘤起源于单克隆,而非真正的碰撞瘤。数据证实,癌性成分是“驱动力”,肉瘤成分源自癌或经历分化的干细胞。因此,子宫癌肉瘤最好被视为化生癌,尽管癌肉瘤这一名称可能会保留。子宫癌肉瘤的辅助治疗可能应与针对侵袭性高级别子宫内膜癌的治疗相似,而非基于肉瘤的治疗。重要的是,一小部分子宫癌肉瘤是真正的碰撞瘤,应予以识别,因为在某些情况下,其预后可能优于相同分期的癌肉瘤。